Skip to main content
SpringerLink
Log in

Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles

  • ASSISTED REPRODUCTION TECHNOLOGIES
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Objective

To evaluate predictive role of day–3 serum anti-Müllerian hormone (AMH) levels and antral follicle count (AFC) in ovarian hyperstimulation syndrome (OHSS) in patients undergoing IVF/ICSI cycles.

Materials and methods

Forty-one women with moderate/severe OHSS and 41 age matched women without OHSS were compared to evaluate the predictive value of certain risk factors for OHSS. AFC, and E2, FSH, LH, AMH, inhibin-B levels measured on day 3 of the menstrual cycle before controlled ovarian hyperstimulation.

Results

Mean FSH was significantly lower (p < 0.0001); and mean LH, AFC and AMH were significantly higher in women with OHSS compared to women without OHSS (p = 0.049, p < 0.0001 and p < 0.0001, respectively). There was no significant difference in inhibin B (p = 0.112) and estradiol (p = 0.706) between the groups. The ROC area under curve (AUC) for AMH presented the largest AUC among the listed risk factors. AMH (AUC = 0.87) and AFC (AUC = 0.74) had moderate accuracy for predicting OHSS while Inhibin B (AUC = 0.58) and LH (AUC = 0.61) had low accuracy. The cut-off value for AMH 3.3 ng/mL provided the highest sensitivity (90%) and specificity (71%) for predicting OHSS. It’s positive (PPV) and negative predictive values (NPV) were 61% and 94%, respectively. The cut-off value for AFC was 8 with 78% sensitivity, 65% specificity, 52% PPV and 86% NPV.

Conclusion

Measurement of basal serum AMH and AFC can be used to determine the women with high risk for OHSS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Forman RG, Frydman R, Egan D, Ross C, Barlow DH. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril. 1990;53:502–9.

    PubMed  CAS  Google Scholar 

  2. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8:559–77.

    Article  PubMed  CAS  Google Scholar 

  3. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249–61.

    PubMed  CAS  Google Scholar 

  4. Delvigne A, Dubois M, Battheu B, Bassil S, Meuleman C, De Sutter P, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod. 1993;8:1361–6.

    PubMed  CAS  Google Scholar 

  5. Schenker JG. Prevention and treatment of ovarian hyperstimulation. Hum Reprod. 1993;8:653–9.

    PubMed  CAS  Google Scholar 

  6. Mathur RS, Joels LA, Akande AV, Jenkins JM. The prevention of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol. 1996;103:740–6.

    Article  PubMed  CAS  Google Scholar 

  7. Aboulghar M. Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS. Hum Reprod. 2003;18:1140–1.

    Article  PubMed  CAS  Google Scholar 

  8. Orvieto R. Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod. 2003;18:665–7.

    Article  PubMed  CAS  Google Scholar 

  9. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005;83:979–87.

    Article  PubMed  Google Scholar 

  10. Peñarrubia J, Fábregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist—gonadotropin treatment. Hum Reprod. 2005;20:915–22.

    Article  PubMed  Google Scholar 

  11. Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA. Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril. 2006;85:1541–3.

    Article  PubMed  Google Scholar 

  12. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007;22:766–71.

    Article  PubMed  Google Scholar 

  13. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod. 2007;22:2414–21.

    Article  PubMed  CAS  Google Scholar 

  14. Vloeberghs V, Peeraer K, Pexsters A, D’Hooghe T. Ovarian hyperstimulation syndrome and complications of ART. Best Pract Res Clin Obstet Gynaecol. 2009;23:691–709.

    Article  PubMed  Google Scholar 

  15. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2006;27:170–207.

    Article  PubMed  Google Scholar 

  16. Fauser BC, Diedrich K, Devroey P. Evian Annual Reproduction Workshop Group 2007. Predictors of ovarian response:progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update. 2008;14:1–14.

    Article  PubMed  CAS  Google Scholar 

  17. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti Mullerian hormone. Reproduction. 2002;124:601–9.

    Article  PubMed  CAS  Google Scholar 

  18. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction. 2006;131:1–9.

    Article  PubMed  CAS  Google Scholar 

  19. Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, et al. Serum anti- Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod. 2008;23:160–7.

    Article  PubMed  CAS  Google Scholar 

  20. Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, et al. Circulating basal anti-Mullerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril. 2009;92:1586–93.

    Article  PubMed  CAS  Google Scholar 

  21. Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011;17(1):46–54.

    Article  PubMed  CAS  Google Scholar 

  22. Bellver J, Escudero E, Pellicer A. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome (OHSS): ovarian mutilating surgery is not an option in the management of severe OHSS. Hum Reprod. 2003;18:1363–7.

    Article  PubMed  Google Scholar 

  23. Tummon I, Gavrilova-Jordan L, Allemand MC, Session D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand. 2005;84:611–6.

    PubMed  Google Scholar 

  24. Danninger B, Brunner M, Obruca A, Feichtinger W. Prediction of ovarian hyperstimulation syndrome by ultrasound volumetric assessment [corrected] of baseline ovarian volume prior to stimulation. Hum Reprod. 1996;11:1597–9.

    PubMed  CAS  Google Scholar 

  25. Kwee J, Elting ME, Schats R, McDonnell J, Lambalk CB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol. 2007;15:5–9.

    Google Scholar 

  26. Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ. Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril. 2007;87:764–75.

    Article  PubMed  Google Scholar 

  27. Hansen KR, Morris JL, Thyer AC, Soules MR. Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting. Fertil Steril. 2003;80(3):577–83.

    Article  PubMed  Google Scholar 

  28. Kwee J, Elting MW, Schats R, Bezemer PD, Lambalk CB, Schoemaker J. Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study. Hum Reprod. 2003;18:1422–7.

    Article  PubMed  CAS  Google Scholar 

  29. Morris RS, Paulson RJ, Sauer MV, Lobo RA. Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Hum Reprod. 1995;10:811–4.

    PubMed  CAS  Google Scholar 

  30. Enskog A, Nilsson L, Brännström M. Peripheral blood concentrations of inhibin B are elevated during gonadotropin stimulation in patients who later develop ovarian OHSS and inhibin A concentrations are elevated after OHSS onset. Hum Reprod. 2000;15:532–8.

    Article  PubMed  CAS  Google Scholar 

  31. Moos J, Rezabek K, Filova V, Moosova M, Pavelkova J, Peknicova J. Comparison of follicular fluid and serum levels of Inhibin A and Inhibin B with calculated indices used as predictive markers of Ovarian Hyperstimulation Syndrome in IVF patients. Reprod Biol Endocrinol. 2009;7:86.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Sevim Purisa and Penbe Cagatay for her assistance in statistics; Hulya Senol for her assistance in collection of the data.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, IVF Unit, Cerrahpasa Medical School, Istanbul University, Fatih, Istanbul, Turkey

    Pelin Ocal, Sezai Sahmay, Tulay Irez, Onur Guralp & Ismail Cepni

  2. Department of Obstetrics and Gynecology, Cumhuriyet University Medical School, Sivas, Turkey

    Meral Cetin

  3. Cerrahpasa Tip Fakultesi, Kadin Hastaliklari ve Dogum Anabilim Dali, Istanbul Universitesi, Fatih, Istanbul, Turkey

    Pelin Ocal

Authors
  1. Pelin Ocal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sezai Sahmay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Meral Cetin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tulay Irez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Onur Guralp
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ismail Cepni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pelin Ocal.

Additional information

Capsule Day–3 serum anti-Müllerian hormone (AMH) levels and antral follicle count (AFC) can predict ovarian hyperstimulation syndrome (OHSS) in patients undergoing IVF/ICSI cycles.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ocal, P., Sahmay, S., Cetin, M. et al. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet 28, 1197–1203 (2011). https://doi.org/10.1007/s10815-011-9627-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-011-9627-4

Keywords

Search

Navigation